These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

961 related items for PubMed ID: 26936941

  • 1. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S, Mattsson N, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [Abstract] [Full Text] [Related]

  • 2. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW, Alzheimer's Disease Neuroimaging Initiative*.
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [Abstract] [Full Text] [Related]

  • 3. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [Abstract] [Full Text] [Related]

  • 4. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM.
    J Alzheimers Dis; 2017 Oct; 55(2):813-822. PubMed ID: 27792012
    [Abstract] [Full Text] [Related]

  • 5. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A, Trzepacz PT, Wang S, Yu P, Case M, Hochstetler H, Witte MM, Degenhardt EK, Dean RA, Alzheimer's Disease Neuroimaging Initiative.
    Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
    [Abstract] [Full Text] [Related]

  • 6. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
    Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative.
    Ann Neurol; 2013 Dec; 74(6):826-36. PubMed ID: 23536396
    [Abstract] [Full Text] [Related]

  • 7. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.
    Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonça A, Otto M, Lleó A, Castelo-Branco M, Santana I, Johansson J, Anderl-Straub S, von Arnim CA, Beer A, Blesa R, Fortea J, Herukka SK, Portelius E, Pannee J, Zetterberg H, Blennow K, Nordberg A.
    Brain; 2016 Sep; 139(Pt 9):2540-53. PubMed ID: 27401520
    [Abstract] [Full Text] [Related]

  • 8. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
    Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, Jack C, Weiner M, Davatzikos C, Shaw LM, Trojanowski JQ, Alzheimer’s Disease Neuroimaging Initiative Investigators.
    JAMA Neurol; 2015 May; 72(5):571-81. PubMed ID: 25822737
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S, AIBL Research Group.
    J Alzheimers Dis; 2015 May; 48(1):175-87. PubMed ID: 26401938
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
    Wang ML, Wei XE, Yu MM, Li PY, Li WB, Alzheimer’s Disease Neuroimaging Initiative.
    Neurosci Lett; 2017 Aug 10; 655():115-120. PubMed ID: 28689050
    [Abstract] [Full Text] [Related]

  • 14. Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease.
    de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F, Chupin M, Lehéricy S, Colliot O, Hahn-Barma V, Samri D, Dubois B, Bottlaender M, Sarazin M.
    Brain; 2011 Jul 10; 134(Pt 7):2036-43. PubMed ID: 21705422
    [Abstract] [Full Text] [Related]

  • 15. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC, Bangen KJ, Delano-Wood L, Nation DA, Furst AJ, Salmon DP, Bondi MW, Alzheimer’s Disease Neuroimaging Initiative.
    J Int Neuropsychol Soc; 2016 Nov 10; 22(10):978-990. PubMed ID: 27903335
    [Abstract] [Full Text] [Related]

  • 16. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
    Manca C, Rivasseau Jonveaux T, Roch V, Marie PY, Karcher G, Lamiral Z, Malaplate C, Verger A.
    J Neurol; 2019 Jul 10; 266(7):1685-1692. PubMed ID: 30963253
    [Abstract] [Full Text] [Related]

  • 17. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 10; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 18. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
    Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, Reiman EM, Jagust WJ.
    J Nucl Med; 2015 Apr 10; 56(4):567-74. PubMed ID: 25745095
    [Abstract] [Full Text] [Related]

  • 19. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R.
    Alzheimers Res Ther; 2018 Sep 19; 10(1):96. PubMed ID: 30231896
    [Abstract] [Full Text] [Related]

  • 20. Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42 /Aβ1-40 ratio - a cross-validation study against amyloid PET.
    Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, Hansson O, Blennow K.
    J Neurochem; 2016 Nov 19; 139(4):651-658. PubMed ID: 27579672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.